Case Report: Successful Treatment With Monoclonal Antibodies in One APDS Patient With Prolonged SARS-CoV-2 Infection Not Responsive to Previous Lines of Treatment
oleh: Beatrice Rivalta, Beatrice Rivalta, Donato Amodio, Carmela Giancotta, Veronica Santilli, Lucia Pacillo, Lucia Pacillo, Paola Zangari, Nicola Cotugno, Nicola Cotugno, Emma Concetta Manno, Andrea Finocchi, Andrea Finocchi, Stefania Bernardi, Luna Colagrossi, Luna Colagrossi, Leonarda Gentile, Leonarda Gentile, Cristina Russo, Cristina Russo, Carlo Federico Perno, Carlo Federico Perno, Paolo Rossi, Paolo Rossi, Caterina Cancrini, Caterina Cancrini, Paolo Palma, Paolo Palma
| Format: | Article |
|---|---|
| Diterbitkan: | Frontiers Media S.A. 2022-06-01 |
Deskripsi
We described the case of a patient affected by activated PI3K-kinase delta syndrome (APDS) and a long-lasting and pauci-symptomatic SARS-CoV-2 infection, treated with multiple therapeutic agents including remdesivir and SARS-CoV-2-neutralizing monoclonal antibodies. We detected the clearance of the virus 105 days from the first positive swab and 7 days after monoclonal antibody administration. At genotyping, the SARS-CoV-2 virus resulted as wild type on all samples tested. This case shows the monoclonal antibodies’ good tolerability and efficacy in reducing viral shedding in long-lasting infections refractory to other treatments.